Q4 2024 13F Holders as of 12/31/2024
-
Type / Class
-
Equity / Common Stock, $0.0001 par value
-
Shares outstanding
-
700K
-
Number of holders
-
4
-
Total 13F shares, excl. options
-
9.91K
-
Shares change
-
+9.91K
-
Total reported value, excl. options
-
$33.4K
-
Value change
-
+$33.4K
-
Number of buys
-
4
-
Price
-
$3.37
Significant Holders of TRANSCODE THERAPEUTICS, INC. - Common Stock, $0.0001 par value (RNAZ) as of Q4 2024
4 filings reported holding RNAZ - TRANSCODE THERAPEUTICS, INC. - Common Stock, $0.0001 par value as of Q4 2024.
TRANSCODE THERAPEUTICS, INC. - Common Stock, $0.0001 par value (RNAZ) has 4 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 9.91K shares
of 700K outstanding shares and own 1.42% of the company stock.
Largest 4 shareholders include UBS Group AG (8.68K shares), Tower Research Capital LLC (TRC) (926 shares), MORGAN STANLEY (304 shares), and BANK OF AMERICA CORP /DE/ (4 shares).
This table shows the top 4 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.